Genetic analysis of chemoresistance in primary murine lymphomas

Nature Medicine

Volumn 6, Issue 9, 2000, Pages 1029-1035

  Schmitt, Clemens A ^a   Rosenthal, Christine T ^a   Lowe, Scott W ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MAFOSFAMIDE; PROTEIN BCL 2; TAXOTERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE TRANSFER; GENETIC ANALYSIS; LONG TERM EXPOSURE; LYMPHOMA; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADAPTATION, BIOLOGICAL; ANIMAL; CLONE CELLS; DRUG RESISTANCE, MULTIPLE; GENE TRANSFER TECHNIQUES; GENES, BCL-2; LYMPHOMA; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS C-MYC; RETROVIRIDAE; SUPPORT, NON-U.S. GOV'T; TISSUE CULTURE; TUMOR CELLS, CULTURED;

EID: 0033826530     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/79542     Document Type: Article

References (35)

1. Brown, J.M. & Wouters, B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59, 1391-1399 (1999).
2. Schmitt, C.A., McCurrach, M.E., de Stanchina, E., Wallace-Brodeur, R.R. & Lowe, S.W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13, 2670-2677 (1999).
3. Bearss, D.J. et al. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogens 19, 1114-1122 (2000).
4. Omer, C.A. et al. Mouse mammary tumor virus-ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res. 60, 2680-2688 (2000).
5. Adams, J.M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533-538 (1985).
6. Harris, A.W. et al. The Eμ-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med. 167, 353-371 (1988).
7. El-Rouby, S. et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82, 3452-3459 (1993).
8. Wattel, E. et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84, 3148-3157 (1994).
9. Ichikawa, A. et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N. Engl. J. Med. 337, 529-534 (1997).
10. Wilson, W.H. et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89, 601-609 (1997).
11. Navaratnam, S. et al. Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas. Leuk. Lymphoma 29, 139-144 (1998).
12. Moller, M.B., Gerdes, A.M., Skjodt, K., Mortensen, L.S. & Pedersen, N.T. Disrupted p53 function as predictor of treatment failure and poor prognosis in B-and T-cell non-Hodgkin's lymphoma. Clin. Cancer Res. 5, 1085-1091 (1999).
13. Prince, V.E. & Rigby, P.W. Derivatives of moloney murine sarcoma virus capable of being transcribed in embryonal carcinoma stem cells have gained a functional Sp1 binding site. J. Virol. 65, 1803-1811 (1991).
14. Yin, D.X. & Schimke, R.T. Bcl-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res. 55, 4922-4928 (1995).
15. Lock, R.B., & Stribinskiene, L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res. 56, 4006-4012 (1996).
16. Kyprianou, N., King, E.D., Bradbury, D. & Rhee, J.G. Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int. J. Cancer 70, 341-348 (1997).
17. Hermine, O. et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87, 265-272 (1996).
18. Reed, J.C. Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Behring Inst. Mitt. 97, 72-100 (1996).
19. Gascoyne, R.D. et al. Prognostic significance of Bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90, 244-251 (1987).
20. Reed, J.C. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin. Hematol. 34 (Suppl. 5), 9-19 (1997).
21. Uckun, F.M. et al. Cellular expression of antiapoptotic Bcl-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 89, 3769-3777 (1997).
22. Liu R., Page, C., Beidler, D.R., Wicha, M.S. & Nunez, G. Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. Am. J. Pathol. 155, 1861-1867 (1999).
23. Walker, A., Taylor, S.T., Hickman, J.A. & Dive, C. Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells. Cancer Res. 57, 1939-1945 (1997).
24. 1 and Bax by tumor microenvironmental factors. J. Natl. Cancer Inst. 92, 18-23 (2000).
25. Namen, A.E. et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 333, 571-573 (1988).
26. Hsu, B. et al. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene 11, 175-179 (1995).
27. Strasser, A., Harris, A.W., Bath, M.L. & Cory, S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348, 331-333 (1990).
28. Bissonnette, R.P., Echeverri, F., Mahboubi, A. & Green, D.R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359, 552-554 (1992).
29. Fanidi, A., Harrington, E.A. & Evan, G.I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359, 554-556 (1992).
30. Schmitt, C.A. & Lowe, S.W. Apoptosis and therapy. J. Pathol. 187, 127-137 (1999).
31. Di Leonardo, A., Linke, S.P., Clarkin, K. & Wahl, G.M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8, 2540-2551 (1994).
32. Waldman, T. et al. Cell-cycle arrest versus death in cancer therapy. Nature Med. 3, 1034-1036 (1997).
33. Chang, B.D. et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 59, 3761-3767 (1999).
34. Pomp, J. et al. Cell density dependent plating efficiency affects outcome and interpretation of colony forming assays. Radiother. Oncol. 40, 121-125 (1996).
35. Serrano, M., Lin, A.E., McCurrach, M.E., Beach, D. & Lowe, S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997).